FEATURES OF REDOX REGULATION IN TUMOR CELLS
Abstract
Endogenous mechanisms of reactive oxygen (ROS) and nitrogen species production and of antioxidant defense systems in tumor cells are analyzed. Increased ROS production is an important regulator of metabolic changes in these cells: enhanced proliferation, apoptosis inhibition, resistance to hypoxia and to cytostatics (doxorubicin, carboplatin, cisplatin, etc.). The most active ROS sources in tumor cells are mitochondria, NAD(P)H oxidases and peroxisomes, which synthesize O2· – and H2O2. In mitochondria, the superoxide anion radical is generated mainly by complexes I and III; membrane NAD(P)H oxidases Nox1, Nox2, Nox3, and Nox5 produce O2· –, Nox4, and dual oxidases DUOX-1, DUOX-2 – mainly H2O2. Increasing ROS stationary concentration activates endogenous antioxidant defense mechanisms, such as redox-dependent antioxidant respons(iv)e element system Keap1/Nrf2/ARE and autophagy, which allows tumor cells to survive under oxidative stress and may underlie resistance to radio- and chemotherapy. The possibilities of tumor cell redox balance regulation by antioxidants with targeted action and by specific inhibitors of ROS enzymatic production are discussed.
Key words
ReferencesAdam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., Baban D., Nye E., Stamp G.W., Wolhuter K., Stevens M., Fischer R., Carmeliet P., Maxwell P.H., Pugh C.W., Frizzell N., Soga T., Kessler B.M., El-Bahrawy M., Ratcliffe P.J., Pollard P.J. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011. 20. (4). 524-537.
Anding A.L., Baehrecke E.H. Cleaning house: Selective autophagy of organelles. Dev. Cell. 2017. 41. (1). 10-22.
Anikin I.V., Popovich I.G., Tyndyk M.L., Zabezhinskiy M.A., Yurova M.N., Skulachev V.P., Anisimov V.N. Effect of plastoquinone derivative SkQ1 on benzo(a)pyrene-induced soft tissue carcinogenesis. Voprosy onkologii = Problems in oncology. 2013. 59. (1). 89-93. [In Russian].
Antonenko Yu.N., Avetisyan A.V., Bakeeva L.E., Chernyak B.V., Chertkov V.A., Domnina L.V., Ivanova O.Yu., Izyumov D.S., Khaylova L. .S., Klishin S.S., Korshunova G.A., Lyamzaev K.G., Muntyan M.S., Nepryakhina OK, Pashkovskaya AA, Pletyushkina O.Yu., Pustovidko A.V., Roginsky V.A., Rokitskaya T.I., Ruuge E.K., Saprunova V.B., Severina I.I., Simonyan R.A., Skulachev I.V., Skulachev M.V., Sumbatyan N.V., Sviryaeva I.V., Tashlitsky V.N., Vasilyev Yu.M., Vysokikh M.Yu., Yaguzhinsky L.S., Zamyatnin A.A., Skulachev V.P. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochemistry (Mosc.). 2008. 73. (12). 1273-1287.
Antony S., Wu Y., Hewitt S.M., Anver M.R., Butcher D., Jiang G., Meitzler J.L., Liu H., Juhasz A., Lu J., Roy K.K., Doroshow J.H. Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody. Free Radic. Biol. Med. 2013. 65. 497-508.
Basak P., Sadhukhan P., Sarkar P., Sil P.C. Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy. Toxicol. Rep. 2017. 4. 306-318.
Battogtokh G., Cho Y.-Y., Lee J.Y., Lee H.S., Kang H.C. Mitochondrial-targeting anticancer agent conjugates and nanocarrier systems for cancer treatment. Front. Pharmacol. 2018. 9.
Bazhin A.V., Yang Y., D'Haese J.G., Werner J., Philippov P.P., Karakhanova S. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Int. J. Cancer. 2016. 139. (1). 130-139.
Best S.A., Sutherland K.D. “Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle. 2018. 17. (14). 1696-1707.
Biasutto L., Mattarei A., Azzolini M., La Spina M., Sassi N., Romio M., Paradisi C., Zoratti M. Resveratrol derivatives as a pharmacological tool. Ann. N. Y. Acad. Sci. 2017. 1403. (1). 27-37.
Bishop E., Bradshaw T.D. Autophagy modulation: a prudent approach in cancer treatment?. Cancer Chemother. Pharmacol. 2018. *.
Bonekamp N.A., Völkl A., Fahimi H.D., Schrader M. Reactive oxygen species and peroxisomes: Struggling for balance. Biofactors. 2009. 35. (4). 346-355.
Breitenbach M., Rinnerthaler M., Weber M., Breitenbach-Koller H., Karl T., Cullen P., Basu S., Haskova D., Hasek J. The defense and signaling role of NADPH oxidases in eukaryotic cells : Review. Wien. Klin. Wochenschr. 2018. 168. (11-12). 286-299.
Cai M., Sun X., Wang W., Lian Z., Wu P., Han S., Chen H., Zhang P. Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells. Cancer Lett. 2018. 421. 82-93.
Cheng G., Zielonka J., McAllister D.M., Mackinnon A.C., Joseph J., Dwinell M.B., Kalyanaraman B. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer. 2013. 13. (1).
Cheng G., Zielonka J., Ouari O., Lopez M., McAllister D., Boyle K., Barrios C.S., Weber J.J., Johnson B.D., Hardy M., Dwinell M.B., Kalyanaraman B. Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res. 2016. 76. (13). 3904-3915.
Chikara S., Nagaprashantha L.D., Singhal J., Horne D., Awasthi S., Singhal S.S. Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment. Cancer Lett. 2018. 413. 122-134.
Cipolla C.M., Lodhi I.J. Peroxisomal dysfunction in age-related diseases. Trends Endocrinol. Metab. 2017. 28. (4). 297-308.
Crosas-Molist E., Bertran E., Sancho P., López-Luque J., Fernando J., Sánchez A., Fernández M., Navarro E., Fabregat I. The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression. Free Radic. Biol. Med. 2014. 69. 338-347.
Dahabieh M.S., Di Pietro E., Jangal M., Goncalves C., Witcher M., Braverman N.E., del Rincón S.V. Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. Biochim. Biophys. Acta. Rev. Cancer. 2018. 1870. (1). 103-121.
de Groot P.M., Wu C.C., Carter B.W., Munden R.F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 2018. 7. (3). 220-233.
Desantis V., Saltarella I., Lamanuzzi A., Mariggio M.A., Racanelli V., Vacca A., Frassanito M.A. Autophagy: A new mechanism of prosurvival and drug resistance in multiple myeloma. Transl. Oncol. 2018. 11. (6). 1350-1357.
Di Meo S., Reed T.T., Venditti P., Victor V.M. Role of ROS and RNS sources in physiological and pathological conditions. Oxid. Med. Cell. Longev. 2016. 2016. 1245049.
Diaz B., Shani G., Pass I., Anderson D., Quintavalle M., Courtneidge S.A. Tks5-dependent, Nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal. 2009. 2. (88). ra53-ra53.
Dickerson T., Jauregui C.E., Teng Y. Friend or foe? Mitochondria as a pharmacological target in cancer treatment. Future Med. Chem. 2017. 9. (18). 2197-2210.
Diebold L., Chandel N.S. Mitochondrial ROS regulation of proliferating cells. Free Radic. Biol. Med. 2016. 100. 86-93.
Filomeni G., De Zio D., Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015. 22. (3). 377-388.
Fukutomi T., Takagi K., Mizushima T., Ohuchi N., Yamamoto M. Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1. Mol. Cell. Biochem. 2014. 34. (5). 832-846.
Galadari S., Rahman A., Pallichankandy S., Thayyullathil F. Reactive oxygen species and cancer paradox: To promote or to suppress?. Free Radic. Biol. Med. 2017. 104. 144-164.
Gao X., Schottker B. Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews. Oncotarget. 2017. 8. (31). 51888-51906.
Gazzano E., Lazzarato L., Rolando B., Kopecka J., Guglielmo S., Costamagna C., Chegaev K., Riganti C. Mitochondrial delivery of phenol substructure triggers mitochondrial depolarization and apoptosis of cancer cells. Front. Pharmacol. 2018. 9. 580.
Graham K.A., Kulawiec M., Owens K.M., Li X., Desouki M.M., Chandra D., Singh K.K. NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol. Ther. 2010. 10. (3). 223-231.
Grivennikova V.G., Vinogradov A.D. Mitochondrial production of reactive oxygen species. Biochemistry (Mosc.). 2013. 78. (13). 1490-1511.
Gwangwa M.V., Joubert A.M., Visagie M.H. Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis. Cell. Mol. Biol. Lett. 2018. 23. (1).
Harrison I.P., Selemidis S. Understanding the biology of reactive oxygen species and their link to cancer: NADPH oxidases as novel pharmacological targets. Clin. Exp. Pharmacol. Physiol. 2014. 41. (8). 533-542.
He L., He T., Farrar S., Ji L., Liu T., Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell. Physiol. Biochem. 2017. 44. (2). 532-553.
Helfinger V., Schröder K. Redox control in cancer development and progression. Mol. Aspects Med. 2018. 63. 88-98.
Hempel N., Trebak M. Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium. 2017. 63. 70-96.
Hong S.-K., Starenki D., Wu P.-K., Park J.-I. Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biol. Ther. 2016. 18. (2). 106-114.
Hu Y., Ju Y., Lin D., Wang Z., Huang Y., Zhang S., Wu C., Jiao S. Mutation of the Nrf2 gene in non-small cell lung cancer. Mol. Biol. Rep. 2012. 39. (4). 4743-4747.
Ichimura Y., Komatsu M. Activation of p62/SQSTM1–Keap1–Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Cancer. Frontiers in Oncology. 2018. 8.
Jayakumar S., Patwardhan R.S., Pal D., Singh B., Sharma D., Kutala V.K., Sandur S.K. Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity. Free Radic. Biol. Med. 2017. 113. 530-538.
Jeddi F., Soozangar N., Sadeghi M.R., Somi M.H., Samadi N. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance. DNA Repair. 2017. 54. 13-21.
Kalinina E.V., Andreev Y.A., Petrova A.S., Lubova K.I., Shtil’ A.A., Chernov N.N., Novichkova M.D., Nurmuradov N.K. Redox-dependent expression of genes encoding NADPH oxidase 5 and the key antioxidant enzymes during formation of drug resistance of tumor cells to cisplatin. Bul. Exp. Biol. Med. 2018. 165. (5). 678–681.
Kalyanaraman B., Cheng G., Hardy M., Ouari O., Bennett B., Zielonka J. Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies. Redox Biol. 2018. 15. 347-362.
Kaur R., Kaur J., Mahajan J., Kumar R., Arora S. Oxidative stress—implications, source and its prevention. Environmental Science and Pollution Research. 2013. 21. (3). 1599-1613.
Kerins M.J., Ooi A. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci. Rep. 2018. 8. (1). 12846.
Kim J., Keum Y.S. NRF2, a key regulator of antioxidants with two faces towards cancer. Oxid. Med. Cell. Longev. 2016. 2016. 2746457.
Kirkpatrick D.L., Powis G. Clinically ealuated cancer drugs inhibiting redox signaling. Antioxid. Redox Signal. 2017. 26. (6). 262-273.
Kitamoto K., Miura Y., Karnan S., Ota A., Konishi H., Hosokawa Y., Sato K. Inhibition of NADPH oxidase 2 induces apoptosis in osteosarcoma: The role of reactive oxygen species in cell proliferation. Oncol. Lett. 2018. 15. (5). 7955–7962.
Li L., Chen Y., Gibson S.B. Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation. Cell. Signal. 2013. 25. (1). 50-65.
Little A.C., Sham D., Hristova M., Danyal K., Heppner D.E., Bauer R.A., Sipsey L.M., Habibovic A., van der Vliet A. DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties. Oncogenesis. 2016. 5. (10). e261-e261.
Little A.C., Sulovari A., Danyal K., Heppner D.E., Seward D.J., van der Vliet A. Paradoxical roles of dual oxidases in cancer biology. Free Radic. Biol. Med. 2017. 110. 117-132.
Liu R., Peng J., Wang H., Li L., Wen X., Tan Y., Zhang L., Wan H., Chen F., Nie X. Oxysophocarpine retards the growth and metastasis of oral squamous cell carcinoma by targeting the Nrf2/HO-1 axis. Cell. Physiol. Biochem. 2018 1717-1733.
Liu-Smith F., Jia J., Zheng Y. UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. Adv. Exp. Med. Biol. 2017. 996. 27-40.
Lu K., Alcivar A.L., Ma J., Foo T.K., Zywea S., Mahdi A., Huo Y., Kensler T.W., Gatza M.L., Xia B. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Res. 2017. 77. (11). 2881-2892.
Marinković M., Šprung M., Buljubašić M., Novak I. Autophagy modulation in cancer: Current knowledge on action and therapy. Oxid. Med. Cell. Longev. 2018. 2018. 1-18.
Martinovich G.G., Martinovich I.V., Vcherashniaya A.V., Zenkov N.K., Menshchikova E.B., Kandalintseva N.V., Cherenkevich S.N. Mechanisms of redox regulation of chemoresistance in tumor cells by phenolic antioxidants. Biophysics. 2017. 62. (6). 942-949.
Menegon S., Columbano A., Giordano S. The dual roles of NRF2 in cancer. Trends Mol. Med. 2016. 22. (7). 578-593.
Menshchikova E.B., Lankin V.Z., Zenkov N.K., Bondar I.A., Krugovykh N.F., Trufakin V.A. Oxidative stress. Prooxidants and antioxidants. Moscow: Slovo, 2006. 556 p. [In Russian].
Menshchikova E.B., Zenkov N.K., Kozhin P.M., Chechushkov A.V., Kovner A.V., Khrapova M.V., Kandalintseva N.V., Martinovich G.G. Synthetic phenolic antioxidant TS-13 inhibits Lewis lung carcinoma growth and potentates the oncolytic effect of doxorubicin. Byulleten' eksperimental'noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2018. 116. (11). 592–597. [In Russian].
Miyata Y., Matsuo T., Sagara Y., Ohba K., Ohyama K., Sakai H. A mini-review of reactive oxygen species in urological cancer: Correlation with NADPH oxidases, angiogenesis, and apoptosis. Int. J. Mol. Sci. 2017. 18. (10). 2214.
Mochizuki T., Furuta S., Mitsushita J., Shang W.H., Ito M., Yokoo Y., Yamaura M., Ishizone S., Nakayama J., Konagai A., Hirose K., Kiyosawa K., Kamata T. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene. 2006. 25. (26). 3699-3707.
Moghtaderi H., Sepehri H., Delphi L., Attari F. Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-231. Bioimpacts. 2018. 8. (3). 185-194.
Morel E., Mehrpour M., Botti J., Dupont N., Hamaï A., Nascimbeni A.C., Codogno P. Autophagy: A druggable process. Annu. Rev. Pharmacol. Toxicol. 2017. 57. (1). 375-398.
Na H.-K., Surh Y.-J. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic. Biol. Med. 2014. 67. 353-365.
Nordgren M., Fransen M. Peroxisomal metabolism and oxidative stress. Biochimie. 2014. 98. 56-62.
Ooi A., Dykema K., Ansari A., Petillo D., Snider J., Kahnoski R., Anema J., Craig D., Carpten J., Teh B.T., Furge K.A. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 2013. 73. (7). 2044-2051.
Orr A.L., Vargas L., Turk C.N., Baaten J.E., Matzen J.T., Dardov V.J., Attle S.J., Li J., Quackenbush D.C., Goncalves R.L.S., Perevoshchikova I.V., Petrassi H.M., Meeusen S.L., Ainscow E.K., Brand M.D. Suppressors of superoxide production from mitochondrial complex III. Nat. Chem. Biol. 2015. 11. (11). 834-836.
Pandey P., Singh A.K., Singh M., Tewari M., Shukla H.S., Gambhir I.S. The see-saw of Keap1-Nrf2 pathway in cancer. Crit. Rev. Oncol. Hematol. 2017. 116. 89-98.
Pavlov V.N., Rakhmatullina I.R., Farkhutdinov R.R., Pushkarev V.A., Danilko K.V., Galimova E.F., Baimurzina J.L., Petrova I.V., Mochalov K.S. Free radical oxidation and carcinogenesis: debatable issues. Kreativnaya khirurgiya i onkologiya = Creative Surgery and Oncology. 2017. 7. (2). 54-61. [In Russian].
Rao V.A., Klein S.R., Bonar S.J., Zielonka J., Mizuno N., Dickey J.S., Keller P.W., Joseph J., Kalyanaraman B., Shacter E. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinine. J. Biol. Chem. 2010. 285. (45). 34447–34459.
Rodic S., Vincent M.D. Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype. Int. J. Cancer. 2017. 142. (3). 440-448.
Roy K., Wu Y., Meitzler Jennifer L., Juhasz A., Liu H., Jiang G., Lu J., Antony S., Doroshow James H. NADPH oxidases and cancer. Clin. Sci. 2015. 128. (12). 863-875.
Rybstein M.D., Bravo-San Pedro J.M., Kroemer G., Galluzzi L. The autophagic network and cancer. Nat. Cell Biol. 2018. 20. (3). 243-251.
Scialò F., Fernández-Ayala D.J., Sanz A. Role of mitochondrial reverse electron transport in ROS signaling: Potential roles in health and disease. Frontiers in Physiology. 2017. 8. 428.
Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA. 2008. 105. (36). 13568-13573.
Taguchi K., Motohashi H., Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011. 16. (2). 123-140.
Takamura A., Komatsu M., Hara T., Sakamoto A., Kishi C., Waguri S., Eishi Y., Hino O., Tanaka K., Mizushima N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011. 25. (8). 795-800.
Tanaka M., Miura Y., Numanami H., Karnan S., Ota A., Konishi H., Hosokawa Y., Hanyuda M. Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species. Oncol. Rep. 2015. 34. (4). 1726-1732.
Teixeira G., Szyndralewiez C., Molango S., Carnesecchi S., Heitz F., Wiesel P., Wood J.M. Therapeutic potential of NADPH oxidase 1/4 inhibitors. Br. J. Pharmacol. 2017. 174. (12). 1647-1669.
Thomas D.C. How the phagocyte NADPH oxidase regulates innate immunity. Free Radic. Biol. Med. 2018. 125. 44-52.
Titova E., Shagieva G., Ivanova O., Domnina L., Domninskaya M., Strelkova O., Khromova N., Kopnin P., Chernyak B., Skulachev V., Dugina V. Mitochondria-targeted antioxidant SkQ1 suppresses fibrosarcoma and rhabdomyosarcoma tumour cell growth. Cell Cycle. 2018. 17. (14). 1797-1811.
Tripathi D.N., Walker C.L. The peroxisome as a cell signaling organelle. Curr. Opin. Cell. Biol. 2016. 39. 109-112.
Urra F.A., Muñoz F., Lovy A., Cárdenas C. The mitochondrial complex(I)ty of cancer. Frontiers in Oncology. 2017. 7. 118.
Walker C.L., Pomatto L.C.D., Tripathi D.N., Davies K.J.A. Redox regulation of homeostasis and proteostasis in peroxisomes. Physiol. Rev. 2018. 98. (1). 89-115.
Wang B., Fu J., Yu T., Xu A., Qin W., Yang Z., Chen Y., Wang H. Contradictory effects of mitochondria- and non-mitochondria-targeted antioxidants on hepatocarcinogenesis by altering DNA repair in mice. Hepatology. 2018. 67. (2). 623-635.
Wang Y.Y., Chen J., Liu X.M., Zhao R., Zhe H. Nrf2-mediated metabolic reprogramming in cancer. Oxid. Med. Cell. Longev. 2018. 2018. 9304091.
Wheaton W.W., Weinberg S.E., Hamanaka R.B., Soberanes S., Sullivan L.B., Anso E., Glasauer A., Dufour E., Mutlu G.M., Budigner G.R.S., Chandel N.S. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014. 3. e02242.
Wohlgemuth S.E., Calvani R., Marzetti E. The interplay between autophagy and mitochondrial dysfunction in oxidative stress-induced cardiac aging and pathology. Journal of Molecular and Cellular Cardiology. 2014. 71. 62-70.
Wu W., Liu F., Wu K., Chen Y., Wu H., Dai G., Zhang W. Lon peptidase 2, peroxisomal (LONP2) contributes to cervical carcinogenesis via oxidative stress. Med. Sci. Mon. 2018. 24. 1310-1320.
Yamamoto T., Nakano H., Shiomi K., Wanibuchi K., Masui H., Takahashi T., Urano Y., Kamata T. Identification and characterization of a novel NADPH oxidase 1 (Nox1) inhibitor that suppresses proliferation of colon and stomach cancer cells. Biol. Pharm. Bull. 2018. 41. (3). 419-426.
Zenkov N.K., Kozhin P.M., Chechushkov A.V., Martinovich G.G., Kandalintseva N.V., Menshchikova E.B. Mazes of Nrf2 regulation. Biochemistry (Mosc.). 2017. 82. (5). 556–564.
Zenkov N.K., Menshchikova E.B., Tkachev V.O. Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc.). 2013. 78. (1). 19–36.
Zhang J., Sun X., Wang L., Wong Y.K., Lee Y.M., Zhou C., Wu G., Zhao T., Yang L., Lu L., Zhong J., Huang D., Wang J. Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 2018. 19. 263-273.
Zhou Y., Wu H., Zhao M., Chang C., Lu Q. The Bach family of transcription factors: A comprehensive review. Clin. Rev. Allergy Immunol. 2016. 50. (3). 345-356.
Menshchikova E.B. – doctor of medical sciences, head of the laboratory of molecular mechanisms of free radical processes, e-mail: lemen@centercem.ru
